Abstract
Purpose: Monotherapy with bosentan (BOS), sitaxsentan (SIT), ambrisentan (AMB), sildenafil (SIL), or iloprost (ILO) is effective treatment for idiopathic PAH (IPAH) and connective tissue disease related (CT-PAH). However, few patients normalise functionally or hemodynamically on monotherapy, and combination therapy is then used. This study reports a National open label experience of varied, sequential, dual therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
